Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an ADOBE stock analysis and talk about the risks and upside potential of ADOBE stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
12 Sept 2025, 22:07 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do an ADOBE stock analysis and talk about the risks and upside potential of ADOBE  stock
Source overview

AI-generated source summary

The video analyzes Adobe (ADBE) following its earnings report, noting a modest 2.6% increase despite being down 40% YOY. The stock's PE ratio has decreased from 55 to 16. The latest report showed beats on EPS ($5.31 vs. $5.18 expected) and revenue ($5.99B vs. $5.91B expected). The company expects EPS between $5.35 and $5.40 for the fourth quarter against analyst estimates of $5.34. The company mentions AI 110 times in the report and the company has annual AI run rate of $3.5 Billion last year. They anticipate $250M ARR for Q4. He shows an Adobe EPS valuation model and believes that ADBE could move up to a price of $693, from the current price of $362, calculating the fail bound price to be $347.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail